TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04778800
Drug: LM-second line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
Study: NCT05943080
Drug: IPACK(0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)
Normalized name: Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is applied to the anatomical space between the posterior capsule and the popliteal artery with the help of USG.
Study: NCT05318820
Drug: HMPL-523
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test \[T\]/Reference\[R\]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product \[i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.\], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).
Study: NCT05478174
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK3486 for induction of general anesthesia
Study: NCT06109948
Drug: Placebo injection for IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo saline injection
Study: NCT04724239
Drug: IBI305
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg/kg IV on Day 1 Q3W
Study: NCT06286423
Drug: Control/Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treated subjects will take 0.6mg of placebo 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of placebo1x per day (or every other day if kidney disease is present) for 76 +/1 days.
Study: NCT06358014
Drug: Fematon (estradiol/estradiol-norethindrone acetate combination tablet package)+SSRIs
Normalized name: estradiol / norethindrone acetate Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the combination group, eligible subjects will receive 1 tablet/day of estradiol/estradiol-norethindrone acetate combination tablet for 8 weeks. The estradiol/estradiol-norethindrone acetate combination tablet will be taken orally before bedtime, 1 tablet/day (trade name: Fematon, Abbott Laboratories, USA, this product is a combination package, with estradiol 1 mg in the first 14 days of each treatment cycle, and estradiol 1 mg and norethindrone acetate 10 mg in the last 14 days of each treatment cycle). This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram.
Study: NCT06358014
Drug: SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs. During the study, medication doses will be quantitatively adjusted based on the results of each visit assessment combined with drug concentrations.
Study: NCT05195528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally via capsule
Study: NCT06088836
Drug: Erector spinae plane block group.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under complete aseptic precautions and sterilization and in sitting position, A high-frequency ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the midline midway between the uppermost and the lowest fractured rib to identify counting of ribs using ultrasound three muscles were identified as superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. However, when the rhomboid major muscle disappears this indicates that we are at the level of the seventh thoracic vertebra.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done. Then, an 18-gauge Tuohy needle was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles
Study: NCT06533605
Drug: SSGJ-706
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific antibody
Study: NCT06237556
Drug: Melatonin 5 MG
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
Study: NCT06464939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applications of water for injection
Study: NCT04620148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo concentrate solution
Study: NCT06386705
Drug: TSN084
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Study: NCT05403229
Drug: Systemic Steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups receive a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.
Study: NCT05098509
Drug: RAD011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol Oral Solution (containing synthetic cannabidiol)
Study: NCT05098509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for RAD011
Study: NCT05042284
Drug: Non-enteric coated pancreatic enzyme preparation
Normalized name: Oryctolagus cuniculus pancreatin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
Study: NCT04999527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
Study: NCT04844528
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral nicotinamide 500 mg twice daily (BID)
Study: NCT04844528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo twice daily for first year. Cross over to oral nicotinamide 500 mg twice daily (BID) for year two.
Study: NCT05501743
Drug: Intra-articular injection of microfat and PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
Study: NCT05579769
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.
Study: NCT05579769
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
Study: NCT05579769
Drug: Bone marrow infusion
Normalized name: Sus scrofa bone marrow preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0
Study: NCT05956509
Drug: Placebo for ABBV-950
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) Injection
Study: NCT00017758
Drug: Pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017758
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05902208
Drug: Antiviral treatment with conventional non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.
Study: NCT05902208
Drug: Placebo with conventional non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
Study: NCT05364762
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05855863
Drug: Ginkgo Ketone Ester Tablets
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo Ketone Ester Tablets taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
Study: NCT05855863
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
Study: NCT04545515
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination (FDC) tablets for oral administration.
Study: NCT06252441
Drug: Rectal Diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Rectal Diclofenac Before ERCP
Study: NCT06252441
Drug: Oral N-acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
Study: NCT01384435
Drug: KPS-0373
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01384435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05133882
Drug: Clifutinib Besylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs
Study: NCT04798716
Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose 2 X 10\^9, 4 X 10\^9, 8 X 10\^9/mL
Study: NCT05874622
Drug: VC005 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 groups repeat administration for 4 weeks
Study: NCT05874622
Drug: VC005 Tablets Placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 placebo groups repeat administration for 4 weeks
Study: NCT05669872
Drug: Ferric Carboxymaltose 50Mg/Ml Inj 20Ml
Normalized name: FERRIC CARBOXYMALTOSE 50MG/ML INJ 20ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ferric carboxymaltose 1000mg, fixed dose for intervention group
Study: NCT05630807
Drug: Bepirovirsen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen will be administered.
Study: NCT06008925
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.
Study: NCT04902235
Drug: Experimental: CRH administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns
Study: NCT04902235
Drug: Control: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)
Study: NCT00002082
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05628740
Drug: 3 mg NOC-100 (via nebulizer)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1
Study: NCT05628740
Drug: 1 mg NOC-110 (via DPI) [1x 1 mg capsule]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
Study: NCT05628740
Drug: Placebo (via DPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule
Study: NCT05628740
Drug: Placebo (via DPI) [2x Placebo capsules]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule
Study: NCT04982029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06207682
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally via tablets
Study: NCT04772248
Drug: TNF Inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: First eligible prescription for treating rheumatoid arthritis (RA)
Study: NCT05887999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06316973
Drug: CS-1103
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-1103 for infusion
Study: NCT06316973
Drug: Sterile Saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Saline for Injection
Study: NCT05120219
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
Study: NCT05120219
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
Study: NCT05120219
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and multiple doses of HR20033 FDC tablet
Study: NCT05784701
Drug: TSCV (Full-strength)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSCV (Full-strength)
Study: NCT05784701
Drug: TSCV (Half-strength)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSCV (Half-strength)
Study: NCT05784701
Drug: Typbar-TCV
Normalized name: Typhoid conjugate vaccine (TCV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typbar-TCV
Study: NCT05784701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05287256
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be orally self-administered by study participants
Study: NCT05015309
Drug: SH3765 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
Study: NCT05287256
Drug: Vaporized Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be self-administered by study participants using a vaporizer
Study: NCT05669092
Drug: XELIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
Study: NCT05669092
Drug: FOLFRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
Study: NCT05915026
Drug: Gadoquatrane (BAY1747846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study: NCT05473533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; formulated as solution for inhalation without active substance.
Study: NCT05473533
Drug: PRS-220
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRS-220; formulated as solution for inhalation.
Study: NCT05155969
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.
Study: NCT04654312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please see arm descriptions
Study: NCT05836610
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous bolus hydrocortisone therapy during hypothermia treatment
Study: NCT04750122
Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of chemotherapy is based on the PTC drug sensitivity results.
Study: NCT06453291
Drug: NSAIDs (Nonsteroidal Anti-Inflammatory Drugs):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Objective: To reduce pain and inflammation associated with chronic low back pain.~Medications: Ibuprofen, Naproxen, or Diclofenac.~Dosage:~Ibuprofen: 400-600 mg every 6-8 hours as needed. Naproxen: 250-500 mg twice daily as needed. Diclofenac: 50 mg three times daily as needed. Administration: Oral tablets. Duration: Daily use as prescribed, for the duration of the study. Monitoring: Regular follow-up visits to monitor pain levels, side effects, and adherence.
Study: NCT06267066
Drug: Vaseline Topical Product
Normalized name: Vaseline Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient
Study: NCT06388551
Drug: LY03017
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, administered orally
Study: NCT06388551
Drug: LY03017-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, administered orally
Study: NCT06368063
Drug: Huaier granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaier Granules: Oral administration, 10g once, 3 times a day, starting from 15-30 days after surgery until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
Study: NCT05074550
Drug: PPMX-T003
Approvals — FDA: no, EMA: no, PMDA: no
Description: As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
Study: NCT04865835
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of placebo
Study: NCT05304559
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
Study: NCT05168007
Drug: WID-RGC20(Cariprazine) 3mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
Study: NCT05168007
Drug: WID-RGC20(Cariprazine) 6mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
Study: NCT05168007
Drug: Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo comparator is administered during the double-blind treatment period(6 weeks).
Study: NCT06274554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsules will be used as a comparator.
Study: NCT04688164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05137795
Drug: ZYESAMI™ (aviptadil acetate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
Study: NCT05137795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Inhalation
Study: NCT06230354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection
Study: NCT06158555
Drug: 250 ML NaCl 4.5 MG/ML Injection
Normalized name: 250 ML NaCl 4.5 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus 250 ml crystalloid. Usually 0.9% saline or compound sodium lactate solution at discretion of attending clinician
Study: NCT06184334
Drug: Solfenacin
Normalized name: solfenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: pills taken once day
Study: NCT05827796
Drug: IN10018
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
Study: NCT05597527
Drug: Fluzopari and apatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzopari was used as 100mg capsules orally twice a day (one time in the morning and one time in the evening), every four weeks as a cycle, a total of 3-4 cycles. Apatinib was used as 250 mg orally once a day, every 4 weeks as a cycle, 2-3 cycles in total, and stop 4 weeks before operation.
Study: NCT05698095
Drug: 5-methoxy-N,N-dimethyltryptamine succinate salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 5-MeO-DMT drug product is comprised of the appropriate concentration of 5-MeO-DMT succinate salt drug substance in solution with 0.9% sodium chloride injection solution (USP) in a 5 mL glass vial, and is administered intramuscularly.
Study: NCT05698095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.
Study: NCT04857866
Drug: XmAb27564
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose of XmAb27564
Study: NCT04857866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo